Patient characteristics | Before September 2017 (n=198) | P-value (Chi- square test) | After September 2017 (n=159) | P-value (Chi- square test) | Difference between % of patients used the study medicines before and after September 2017 p-value (Chi-square test) | |||||
---|---|---|---|---|---|---|---|---|---|---|
No. of patients not used the study medicines (n=124) | No. of patients used the study medicines (n=74) | The proportion of patients used the study medicines(%) | No. of patients not used the study medicines (n=49) | No. of patients used the study medicines (n=110) | The proportion of patients used the study medicines (%) | |||||
Age | <40 years old | 6 (4.9) | 7 (9.3) | 53.8 | 0.33 | 4 (0.08) | 12 (10.9) | 75.0 | 0.03 | 0.27 |
40-49 years old | 30 (24.4) | 21 (29.2) | 41.2 | 8 (16.3) | 36 (32.7) | 81.8 | <0.01 | |||
50-59 years old | 49 (39.8) | 30 (40.0) | 38.0 | 21 (42.8) | 42 (38.1) | 66.7 | <0.01 | |||
>60 years old | 39 (30.9) | 16 (21.3) | 29.1 | 16 (32.6) | 20 (18.2) | 55.6 | <0.01 | |||
Household registration | Urban | 46 (37.4) | 40 (53.3) | 46.5 | 0.03 | 30 (61.2) | 69 (60.9) | 69.7 | 0.96 | <0.01 |
Rural | 78 (62.6) | 34 (46.7) | 31.3 | 19 (38.7) | 41 (39.1) | 68.3 | <0.01 | |||
Level of disposable income of the patient residential area | Low | 47 (39.4) | 16 (21.3) | 25.8 | 0.01 | 17 (34.6) | 34 (30.9) | 66.7 | 0.04 | <0.01 |
Middle | 52 (42.3) | 33 (45.3) | 39.5 | 18 (36.7) | 38 (34.5) | 67.9 | <0.01 | |||
High | 25 (20.3) | 25 (33.3) | 50.0 | 8 (16.3) | 38 (34.5) | 82.6 | <0.01 | |||
Types of health insurance program | Urban employee | 30 (24.4) | 30 (40.0) | 50.0 | 0.02 | 20 (40.8) | 52 (47.3) | 72.2 | 0.32 | <0.01 |
Urban/Rural residents | 76 (61.0) | 35 (48.0) | 32.4 | 15 (30.6) | 43 (39.1) | 74.1 | <0.01 | |||
Non-insured | 18 (14.6) | 9 (12.0) | 33.3 | 9 (18.3) | 15 (13.6) | 62.5 | 0.04 | |||
Local patients | Yes | 76 (61.8) | 51 (68.0) | 40.2 | 0.38 | 24 (49.0) | 70 (63.6) | 74.5 | 0.17 | <0.01 |
No | 48 (38.2) | 23 (32.0) | 33.8 | 25 (51.0) | 40 (36.4) | 61.5 | <0.01 | |||
Tumour progression stage | I | 18 (14.6) | 14 (18.7) | 43.8 | 0.76 | 9 (18.3) | 23 (21.0) | 71.8 | 0.04 | 0.01 |
II | 68 (54.5) | 36 (49.3) | 35.6 | 26 (53.0) | 60 (54.5) | 69.8 | <0.01 | |||
III | 29 (23.6) | 20 (26.7) | 40.8 | 14 (28.6) | 20 (18.2) | 58.8 | 0.03 | |||
IV | 9 (7.3) | 4 (5.3) | 30.8 | 0 (0.0) | 7 (6.3) | 100.0 | 0.01 | |||
124 | 74 | 37.4 | 49 | 110 | 69.2 |